Novartis Seeks To Fracture Class In Bone Drug Suit

Law360, New York (August 13, 2007, 12:00 AM EDT) -- Locked in a battle over bone cancer drugs Aredia and Zometa, Novartis Pharmaceutical Corp. has asked the district judge overseeing the multidistrict product liability litigation to break apart a current class of plaintiffs and allow them to pursue their claims individually.

The pharmaceutical giant filed a request Friday to have the court sever the class in the case, arguing that the plaintiffs should not still be fused together in the wake of a recent dismissal of allegations.

“Because plaintiffs do not meet the standard for permissive...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.